Clinician Guidance on the Benefits of Healthy Nutrition and Increased Physical Activity for People With Type 2 Diabetes Following Glucagon-Like Peptide 1 Receptor Agonist Initiation

Glucagon-like peptide 1 (GLP-1) receptor agonists are prescribed as an adjunct to diet and exercise for the management of type 2 diabetes, yet adherence to healthy nutrition and physical activity is often suboptimal. As the use of these agents continues to rise, there are some concerns about the negative aspects of associated weight loss, including loss of muscle mass. This article highlights the benefits of healthy nutrition and physical activity for type 2 diabetes management irrespective of GLP-1 receptor agonist use or associated weight loss, identifies barriers to healthy nutrition and physical activity, and provides guidance for primary care clinicians to further educate and advise their patients on these important topics when initiating GLP-1 receptor agonist treatment.

Authors

Institutions

Publication Details

Journal
Clinical Diabetes
Published
2025-08-28
DOI
https://doi.org/10.2337/cd25-0037
Primary Topic
Diabetes Treatment and Management
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Clinician Guidance on the Benefits of Healthy Nutrition and Increased Physical Activity for People With Type 2 Diabetes Following Glucagon-Like Peptide 1 Receptor Agonist Initiation

Javier Morales, Pamela Kushner, Aaron King, Davida Kruger et al.
3 links
Clinical Diabetes
Diabetes Treatment and Management
article

Clinician Guidance on the Benefits of Healthy Nutrition and Increased Physical Activity for People With Type 2 Diabetes Following Glucagon-Like Peptide 1 Receptor Agonist Initiation

Javier Morales, Pamela Kushner, Aaron King, Davida Kruger, Carlos Campos
article en

Abstract

Glucagon-like peptide 1 (GLP-1) receptor agonists are prescribed as an adjunct to diet and exercise for the management of type 2 diabetes, yet adherence to healthy nutrition and physical activity is often suboptimal. As the use of these agents continues to rise, there are some concerns about the negative aspects of associated weight loss, including loss of muscle mass. This article highlights the benefits of healthy nutrition and physical activity for type 2 diabetes management irrespective of GLP-1 receptor agonist use or associated weight loss, identifies barriers to healthy nutrition and physical activity, and provides guidance for primary care clinicians to further educate and advise their patients on these important topics when initiating GLP-1 receptor agonist treatment.

Clinical DiabetesVol. 43(5)
Hofstra University (US), Henry Ford Health System (US), The University of Texas at San Antonio Health Science Center (US), Baptist Health System (US), University of California, Irvine Medical Center (US), Donald & Barbara Zucker School of Medicine at Hofstra/Northwell (US)
Eli Lilly and Company, AstraZeneca, MannKind Corporation, Dexcom, Novo Nordisk, Astellas Pharma
Openalex Percentile: Top 69%
Diabetes Treatment and Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Clinician Guidance on the Benefits of Healthy Nutrition and Increased Physical Activity for People With Type 2 Diabetes Following Glucagon-Like Peptide 1 Receptor Agonist Initiation — Javier Morales, Pamela Kushner, et al. · Clinical Diabetes (2025) | TGRS Research Map | TGRS